Jeil Pharm Total Liabilities
Jeil Pharm total liabilities. Based on the latest financial reports, Jeil Pharm (002620) has total liabilities worth ₩421.10 Billion KRW (≈ $285.37 Million USD) as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check 002620 asset liquidity ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Jeil Pharm (2011–2025)
Total liabilities of Jeil Pharm from 2011 to 2025. This chart illustrates how Jeil Pharm's total liabilities have evolved over time, based on quarterly financial data. Explore Jeil Pharm long-term investment intensity to see how much of total assets are deployed in long-term investments.
Jeil Pharm Competitors by Total Liabilities
The table below lists competitors of Jeil Pharm ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
HEMARAJ INDUSTRIAL PROPERTY AND LEASEHOLD FUND
BK:HPF
|
Thailand | ฿95.60 Million |
|
Shanghai Shibei Hi-Tech Co Ltd B
SHG:900902
|
China | $12.13 Billion |
|
GCL Global Holdings Ltd Ordinary Shares
NASDAQ:GCL
|
USA | $123.85 Million |
|
NOVATECH Co. Ltd
KQ:285490
|
Korea | ₩34.24 Billion |
|
Europap Tezol Kagit Sanayi Ve Ticaret AS
IS:TEZOL
|
Turkey | TL1.56 Billion |
|
Adtraction Group AB
ST:ADTR
|
Sweden | Skr287.52 Million |
|
Lautan Luas Tbk
JK:LTLS
|
Indonesia | Rp4.06 Trillion |
|
Handok
KO:002390
|
Korea | ₩530.85 Billion |
Liability Composition Analysis (2011–2025)
This chart breaks down Jeil Pharm's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see 002620 asset base.
Liquidity & Leverage Metrics
Jeil Pharm Total Liabilities Ratios Explained
Jeil Pharm total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.20 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.34 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.47 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Jeil Pharm's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Jeil Pharm (2011–2025)
The table below shows the annual total liabilities of Jeil Pharm from 2011 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | ₩407.55 Billion ≈ $276.19 Million |
-10.04% |
| 2024-12-31 | ₩453.04 Billion ≈ $307.02 Million |
-5.19% |
| 2023-12-31 | ₩477.81 Billion ≈ $323.81 Million |
+7.16% |
| 2022-12-31 | ₩445.88 Billion ≈ $302.17 Million |
+13.71% |
| 2021-12-31 | ₩392.11 Billion ≈ $265.73 Million |
+1.03% |
| 2020-12-31 | ₩388.11 Billion ≈ $263.02 Million |
+6.79% |
| 2019-12-31 | ₩363.44 Billion ≈ $246.30 Million |
+9.96% |
| 2018-12-31 | ₩330.51 Billion ≈ $223.98 Million |
+1117.39% |
| 2017-12-31 | ₩27.15 Billion ≈ $18.40 Million |
-88.68% |
| 2016-12-31 | ₩239.91 Billion ≈ $162.58 Million |
+17.73% |
| 2015-12-31 | ₩203.78 Billion ≈ $138.10 Million |
+36.43% |
| 2012-12-31 | ₩149.36 Billion ≈ $101.22 Million |
-2.21% |
| 2011-12-31 | ₩152.74 Billion ≈ $103.51 Million |
-- |
About Jeil Pharm
Jeil Pharma Holdings Inc manufactures and sells ingredients of drugs, incrementally modified drugs, and generic drugs in South Korea. The company offers active pharmaceutical ingredients in the areas of antibiotics, gastrointestinal, cardiovascular, neuropsychiatry, oncology, endocrinology, urology, antiviral, and antihistamines, as well as patch products. It also provides finished dosage forms i… Read more